A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of The Journal of Nuclear Medicine. A tumor pretreatment regimen prior to administration of targeted alpha-radioimmunotherapy resulted in durable major responses including histologic cure with minimal toxicity, paving the way for a safer and more effective treatment option for breast cancer patients.
Please follow and like us:
